Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors

A M Petit, J Rak, M C Hung, P Rockwell, N Goldstein, B Fendly, R S Kerbel, A M Petit, J Rak, M C Hung, P Rockwell, N Goldstein, B Fendly, R S Kerbel

Abstract

The overexpression in tumor cells of (proto)-oncogenic receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) or ErbB2/neu (also known as HER-2) is generally thought to contribute to the development of solid tumors primarily through their effects on promoting uncontrolled cell proliferation. However, agents that antagonize the function of the protein products encoded by these (proto)-oncogenes are known to behave in vivo in a cytotoxic-like manner. This implies that such oncogenes may regulate critical cell survival functions, including angiogenesis. The latter could occur as a consequence of regulation of relevant growth factors by such oncogenes. We therefore sought to determine whether EGFR or ErbB2/neu may contribute to tumor angiogenesis by examining their effects on the expression of vascular endothelial cell growth factor (VEGF)/vascular permeability factor (VPF), one of the most important of all known inducers of tumor angiogenesis. We found that in vitro treatment of EGFR-positive A431 human epidermoid carcinoma cells, which are known to be heavily dependent on VEGF/VPF in vivo as an angiogenesis growth factor, with the C225 anti-EGFR neutralizing antibody caused a dose-dependent inhibition of VEGF protein expression. Prominent suppression of VEGF/VPF expression in vivo, as well as a significant reduction in tumor blood vessel counts, were also observed in established A431 tumors shortly after injection of the antibody as few as four times into nude mice. Transformation of NIH 3T3 fibroblasts with mutant ErbB2/neu, another EGFR-like oncogenic tyrosine kinase, resulted in a significant induction of VEGF/VPF, and the magnitude of this effect was further elevated by hypoxia. Moreover, treatment of ErbB2/neu-positive SKBR-3 human breast cancer cells in vitro with a specific neutralizing anti-ErbB2/neu monoclonal antibody (4D5) resulted in a dose-dependent reduction of VEGF/VPF protein expression. Taken together, the results suggest that oncogenic properties of EGFR and ErbB2/neu may, at least in part, be mediated by stimulation of tumor angiogenesis by up-regulating potent angiogenesis growth factors such as VEGF/VPF. These genetic changes may cooperate with epigenetic/environmental effects such as hypoxia to maximally stimulate VEGF/VPF expression. Therapeutic disruption of EGFR or ErbB2/neu protein function in vivo may therefore result in partial suppression of angiogenesis, a feature that could enhance the therapeutic index of such agents in vivo and endow them with anti-tumor effects, the magnitude of which may be out of proportion with their observed cytostatic effects in monolayer tissue culture.

References

    1. Cell. 1982 Apr;28(4):865-71
    1. Eur J Cancer. 1996 Dec;32A(14):2438-50
    1. Cell. 1985 Jul;41(3):697-706
    1. Cell. 1986 Jun 6;45(5):649-57
    1. J Natl Cancer Inst. 1997 Mar 5;89(5):341-3
    1. Oncogene. 1997 Mar 27;14(12):1495-502
    1. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8761-6
    1. Clin Cancer Res. 1995 Aug;1(8):813-21
    1. Clin Cancer Res. 1995 Nov;1(11):1311-8
    1. Clin Cancer Res. 1996 Aug;2(8):1417-25
    1. J Natl Cancer Inst. 1989 Apr 19;81(8):570-6
    1. Nature. 1989 May 4;339(6219):58-61
    1. Cell. 1989 Jul 28;58(2):287-92
    1. Cancer Res. 1990 Mar 1;50(5):1550-8
    1. Mol Biol Cell. 1993 Jan;4(1):121-33
    1. Science. 1993 Jun 25;260(5116):1934-7
    1. J Biol Chem. 1994 Feb 11;269(6):4355-9
    1. Oncogene. 1995 May 18;10(10):1947-54
    1. Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
    1. Cancer Res. 1995 Oct 15;55(20):4575-80
    1. J Biol Chem. 1995 Oct 27;270(43):25915-9
    1. Breast Cancer Res Treat. 1995;36(2):127-37
    1. Nat Med. 1995 Aug;1(8):792-7
    1. Nat Med. 1995 Oct;1(10):1024-8
    1. J Cell Biol. 1995 Dec;131(6 Pt 1):1587-98
    1. Nature. 1996 Apr 4;380(6573):439-42
    1. Cancer Res. 1996 Apr 1;56(7):1615-20
    1. Cancer. 1996 Apr 15;77(8):1419-26
    1. Nat Med. 1996 Jun;2(6):668-75
    1. Br J Cancer. 1996 Jun;73(11):1362-5
    1. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502-7
    1. Cancer Res. 1996 Aug 1;56(15):3436-40
    1. Adv Cancer Res. 1996;69:135-74
    1. J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6
    1. Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6
    1. Cancer Res. 1997 Feb 15;57(4):708-13
    1. EMBO J. 1997 Feb 17;16(4):750-9
    1. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1337-41

Source: PubMed

3
Iratkozz fel